You need to be logged in to see the full monograph.


Date of issue: January 2020, Version: 3

bumps logo
A corresponding patient information leaflet on USE OF LAMOTRIGINE IN PREGNANCY is available.

Lamotrigine is an anticonvulsant used either as sole treatment or as adjunctive treatment of focal and generalized seizures, including tonic-clonic seizures and seizures associated with Lennox-Gastaut syndrome. Lamotrigine is also used in the treatment of bipolar disorder.

The available data on lamotrigine use in pregnancy are derived mainly from studies of women with epilepsy. Overall congenital malformation rates have been studied in over 12,800 infants exposed to lamotrigine in early pregnancy; the majority of the data do not provide evidence that lamotrigine use is associated with an increased risk of overall malformation or a number of specific malformations.

There is currently no credible evidence suggesting an increased risk of miscarriage, stillbirth, premature delivery or small for gestational age infants following exposure to lamotrigine. Data regarding adverse neurodevelopmental outcomes following prenatal exposure to lamotrigine are generally reassuring. There are currently no studies which provide evidence of an increased rate of autism diagnoses following prenatal exposure to lamotrigine; however, some studies have reported an increased rate of autism symptoms. Further research is required to confirm or refute this finding.

Lamotrigine is a weak folate antagonist and a single study has reported a statistically significant increased risk of overall malformation in children born to mothers taking lamotrigine who were prescribed <5mg folic acid per day. UK guidelines state that women who take any antiepileptic medication should be prescribed high dose folic acid (5mg).

Use of any centrally acting drug throughout pregnancy or near delivery may be associated with an increased risk of poor neonatal adaptation syndrome (PNAS). These symptoms are likely to be more severe in infants exposed in utero to more than one CNS acting drug. Where lamotrigine has been used during the latter stages of pregnancy, particularly in combination with other CNS acting medications, delivery should be planned in a unit with adequate neonatal facilities.

Plasma concentrations of lamotrigine have been shown to decline as pregnancy progresses and regular clinical review of women taking lamotrigine is therefore recommended. The lamotrigine dose may need to be increased on the basis of plasma-drug concentration monitoring or according to clinical response to maintain seizure control, particularly in later pregnancy.

Lamotrigine should only be used during pregnancy where the benefits of treatment are considered to outweigh any potential risks. Other risk factors may be also present in individual cases which may independently increase the risk of adverse pregnancy outcome. Clinicians are reminded of the importance of consideration of such factors when performing case-specific risk assessments.

This is a summary of the full UKTIS monograph for health care professionals and should not be used in isolation. The full UKTIS monograph and access to any hyperlinked related documents is available to NHS health care professionals who are logged in.

If you have a patient with exposure to a drug or chemical and require assistance in making a patient-specific risk assessment, please telephone UKTIS on 0344 892 0909 to discuss the case with a teratology specialist.

If you would like to report a pregnancy to UKTIS please click here to download our pregnancy reporting form. Please encourage all women to complete an online reporting form.

Disclaimer: Every effort has been made to ensure that this monograph was accurate and up-to-date at the time of writing, however it cannot cover every eventuality and the information providers cannot be held responsible for any adverse outcomes of the measures recommended. The final decision regarding which treatment is used for an individual patient remains the clinical responsibility of the prescriber. This material may be freely reproduced for education and not for profit purposes within the UK National Health Service, however no linking to this website or reproduction by or for commercial organisations is permitted without the express written permission of this service. This document is regularly reviewed and updated. Only use UKTIS monographs downloaded directly from to ensure you are using the most up-to-date version.